First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Completed
Merck KGaA
Phase 1
2009-11-30
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore
MSC2156119J, in subjects with advanced solid tumors who have not responded to previous
therapies or for whom no other therapies are available.
Subjects will be assigned one of the dosing regimens:
- Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment
(21-day cycle)
- Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks
(21-day cycle)
- Regimen 3: MSC2156119J every day for three weeks (21-day cycle)
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Completed
Merck KGaA, Darmstadt, Germany
Phase 1
2009-11-30
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore
MSC2156119J, in subjects with advanced solid tumors who have not responded to previous
therapies or for whom no other therapies are available.
Subjects will be assigned one of the dosing regimens:
- Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment
(21-day cycle)
- Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks
(21-day cycle)
- Regimen 3: MSC2156119J every day for three weeks (21-day cycle)
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Completed
EMD Serono
Phase 1
2009-11-30
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore
MSC2156119J, in subjects with advanced solid tumors who have not responded to previous
therapies or for whom no other therapies are available.
Subjects will be assigned one of the dosing regimens:
- Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment
(21-day cycle)
- Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks
(21-day cycle)
- Regimen 3: MSC2156119J every day for three weeks (21-day cycle)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
